1 / 36

Integrative Approaches to Treating Prostate Cancer and Prostatitis

Integrative Approaches to Treating Prostate Cancer and Prostatitis. Prostate Cancer. Patterns of Prostate Cancer Physiological vs. Pathological Maintenance vs. Cure Supplements & Adjuvant Therapy. Prostate Cancer General Guidelines. Grade of the Disease Stage of the Disease PSA

merv
Download Presentation

Integrative Approaches to Treating Prostate Cancer and Prostatitis

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Integrative Approaches to Treating Prostate Cancer and Prostatitis

  2. Prostate Cancer • Patterns of Prostate Cancer • Physiological vs. Pathological • Maintenance vs. Cure • Supplements & Adjuvant Therapy

  3. Prostate Cancer General Guidelines • Grade of the Disease • Stage of the Disease • PSA • Therapeutic Surgery, Radiation, Hormonal • Hormonal Refractory Disease • Grade & State of the Person

  4. Prostate Cancer-Stages • Biopsy • Watchful Waiting • Local Therapy • Hormonal Therapy • Androgen Independent • Advanced Disease

  5. Prostate Cancer Evaluation • History: Risk Factors, Family History, Age, Ethnicity • Physical Exam - Digital Rectal Exam • PSA - Discussion • Laboratory Testing

  6. History • Big Picture • Details • Flow • Timing & Rhythms

  7. Physical Exam • Traditional • Temperature Distribution • Excess & Deficiencies • Relationships • Pulse Diagnosis • Tongue Diagnosis

  8. Laboratory Testing • General • Cancer Specific

  9. Laboratory Testing - Continued • General • Circulation • Inflammation • Hormonal • Metabolic • Immune • Cancer Markers

  10. Circulation & Inflammation • LP(a) • CRP • Fibrinogen • Galectin-3 • Homocysteine • PT/PTT • IL-8, IL-6

  11. Cancer Markers • The more you test, the better

  12. Laboratory Testing Prostate Cancer • CBC • Comp Metabolic Panel • Lipid Panel • Lipo (a) • PSA Free/Total • PCA-3 • PAP • Fibrinogen • Testosterone Free/Total • Dihydrotestosterone (DHT) • Estrone Sulfate • Estradiol • Total Estrogens • Progesterone • Prolactin • Thyroid - TSH, Others • HbA1-C • IGF-1 • Fasting insulin • C-reactive protein (CRP) • Homocysteine • Urine Deoxypyridinoline (DpD) • Urine Pyridinium Crosslinks • Carcinoembryonic Antigen (CEA) • Luteinizing hormone (LH) • Galectin-3 • Other testing: • 24 hour urine hormone evaluation with estrogen metabolites • Heavy metal urine challenge test

  13. Immune • CBC with Differential • IL-2 • IL-6 • IL-8 • NK Cells

  14. Metabolic • IGF-1 • Insulin • HbA1C • Cortisol • Thyroid Panel • Urine DpD • Melatonin • Others

  15. Imaging: General & Cancer Specific • MRI • MRI-S • PET vs CT • Color Doppler Ultrasound • Prostascint Scan • Bone Scan

  16. Approaches & Strategies • Prevention of Metastasis & Angiogenesis • Immune Enhancement • Hormonal & Metabolic Modulation • Direct Cytotoxicity • Antioxidants, Anti Inflammatory & Anti Microbial • Detoxification • Circulation & Hyper Viscosity Improvement • Redifferentiation

  17. Prevention of Metastasis and Angiogenesis withModified Citrus Pectin

  18. Modified Citrus PectinProstate Cancer Research Published Clinical and Preclinical Data

  19. Inhibition of Spontaneous Metastasis in a Rat Prostate Model by Oral Administration of Modified Citrus Pectin Pienta KJ, Naik H, Akhtar A, Yamazaki K, Replogle, TS, Lehr J, Donat TL, Tait L, Hogan V, Raz A Wayne State University School of Medicine, Detroit, MI, USAJ Natl Cancer Inst 1995 87(5):348-53. Method: MCP’s inhibition of prostate cell adhesion to endothelial cells. 0.1% and 1.0% MCP in rats’ drinking water; controls had plain water Results: Significant reduction in lung metastases -- 50% reduction in 0.1% group; 56% reduction in 1.0% group (P<0.03 & P<0.001). Conclusion: MCP acted as potent inhibitor of spontaneous prostate carcinoma metastasis.

  20. Effect of Modified Citrus Pectin on PSA Doubling Time in Prostate Cancer Patients: A Pilot Clinical Trial • Method: MCP 15 g/day to patients with biochemical relapse post local therapy. PSA Doubling Time (PSADT) evaluated at intervals. • Results: MCP significantly increased PSADT in prostate cancer patients. Strum S, Scholz M, McDermed J, McCulloch M, Eliaz, I Prostate Oncology Specialist, Marina del Rey, CA, USA Amitabha Medical Clinic & Healing Center, Sebastopol, CA, USA EcoNugenics, Santa Rosa, CA, USA. International Conference on Diet & The Prevention of Cancer 1999, Tampere, Finland.

  21. Pilot Clinical Results: MCP’s Effect on PSA Doubling Time

  22. Method: 10 men with biochemical prostate cancer relapse used MCP: 15g daily for 1 year. Results: MCP significantly increased PSADT in 7 out of the 10 participants (p<0.01). Modified Citrus Pectin Increases the Prostate-Specific Antigen Doubling Time in Men with Prostate Cancer: A Phase II Pilot Study Guess BW, Scholz MC, Strum SB, Lam RY, Johnson HJ, Jennrich RI Healing Touch Oncology, Marina del Rey, CA, USA Prostate Cancer & Prostatic Disease 2003;6(4):301-4.

  23. Phase II Study: PSADT Results After 1 Year 968 % * *

  24. Using Splines to Detect Changes in PSA Doubling Times Guess B, Jennrich R, Johnson H, Redheffer R, Scholz M, Healing Touch Oncology, Marin del Ray, CA, Department of Statistics, UCLA, CA, The Prostate 2003 54:88-95.

  25. Typical Patient Results MCP

  26. Clinical Benefit in Patients with Advanced Solid Tumors Treated with Modified Citrus Pectin Azémar M, Hildenbrand B, Haering B, Heim ME, Unger C, Albert-Ludwigs-University in Freiburg, Germany, Sonnenberg-Klinik, Bad Sooden-Allendorf, Germany • Method: MCP 15g daily. • Results: 49 patients with advanced solid tumors. 29 evaluated after 2 months -- 21% showed stabilization & improvements in quality of life. • One patient w/ metastasized prostate carcinoma showed 50% decrease in PSA, with significant increase in quality of life & decrease in pain. • Conclusion: MCP shows clinical benefits & improvements in quality of life in advanced cancer patients.

  27. Immune Enhancement in Prostate Cancer Treatment

  28. Immune Enhancement Medicinal Mushrooms Modified Citrus Pectin Honokiol Botanicals - Astragalus, Eleutherococcus, Others BCG (Bacillus Calmette-Guérin) Vaccine

  29. Direct Cytotoxicity

  30. Direct Cytotoxicity in Prostate Cancer Treatment Curcumin, Green Tea Extracts Ban Zhi Lian (Scutellariae barbata) Artemisinin MCP Honokiol MCP + Honokiol Others

  31. Effect of Honokiol on Growth of PC3 Cells (Pre-Published data)

  32. Synergistic Effect of MCP & Honokiol on PC3 Cell Line Migration (Pre-Published Data)

  33. A B Poly Botanical & MCP Effect on Migration of Human Prostate Cancer Cells Poly Botanical The invasive behavior of PC3 evaluated using migration assay in the presence of (A) MCP (mg/mL) & (B) MCP (mg/mL) plus Poly Botanical (10 ug/mL).

  34. Circulation andHyperviscosity Improvement in Prostate Cancer Treatment

  35. Medications, Supplements & Approaches Aspirin Clopidogrel LMW Heparin Nattokinase Lumbrokinase Botanicals Exercise

  36. Redifferentiation Vitamin D3 Sodium Phenyl Butyrate (SPB) Honokiol

More Related